The University of Chicago Header Logo

Connection

Peter H. O'Donnell to Mutation

This is a "connection" page, showing publications Peter H. O'Donnell has written about Mutation.
Connection Strength

0.412
  1. Afatinib Activity in Platinum-Refractory Metastatic Urothelial Carcinoma in Patients With ERBB Alterations. J Clin Oncol. 2016 06 20; 34(18):2165-71.
    View in: PubMed
    Score: 0.236
  2. Mocetinostat for patients with previously treated, locally advanced/metastatic urothelial carcinoma and inactivating alterations of acetyltransferase genes. Cancer. 2019 02 15; 125(4):533-540.
    View in: PubMed
    Score: 0.071
  3. Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival. Clin Cancer Res. 2014 Dec 15; 20(24):6605-17.
    View in: PubMed
    Score: 0.053
  4. Clonal Hematopoiesis in Related Allogeneic Transplant Donors: Implications for Screening and Management. Biol Blood Marrow Transplant. 2020 06; 26(6):e142-e144.
    View in: PubMed
    Score: 0.019
  5. CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. Cancer Rep (Hoboken). 2018 06; 1(1):e1002.
    View in: PubMed
    Score: 0.017
  6. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016 May 07; 387(10031):1909-20.
    View in: PubMed
    Score: 0.015
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.